Antidyslipidemic effects of a farnesoid X receptor antagonist in primates

Life Sciences

Volumn 106, Issue 1-2, 2014, Pages 25-31

  Amano, Yuichiro ^a   Shimada, Mitsuyuki ^a   Miura, Shotaro ^a   Adachi, Ryutaro ^a   Tozawa, Ryuichi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Cholestyramine; Ezetimibe; Farnesoid X receptor antagonist; HDL cholesterol; LDL cholesterol; Torcetrapib

Indexed keywords

7 ALPHA HYDROXY 4 CHOLESTEN 3 ONE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLESTYRAMINE; EZETIMIBE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR ANTAGONIST; FECES LIPID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR BLOCKING AGENT; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDYSLIPIDEMIC ACTIVITY; ARTICLE; CATABOLISM; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DYSLIPIDEMIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID BLOOD LEVEL; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MACACA FASCICULARIS; MALE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALIA; MACACA FASCICULARIS; PRIMATES;

CHOLESTYRAMINE; EZETIMIBE; FARNESOID X RECEPTOR ANTAGONIST; HDL CHOLESTEROL; LDL CHOLESTEROL; TORCETRAPIB;

ANIMALS; ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; MACACA FASCICULARIS; MALE; PRIMATES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME;

EID: 84901692493     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.04.019     Document Type: Article

References (28)

1. Y. Amano, M. Shimada, S. Miura, R. Adachi, and R. Tozawa Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates Eur J Pharmacol 723 2014 108 115
2. M.E. Brousseau, M.R. Diffenderfer, J.S. Millar, C. Nartsupha, B.F. Asztalos, and F.K. Welty et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion Arterioscler Thromb Vasc Biol 25 2005 1057 1064 (Pubitemid 40627855)
3. B. Cariou, and B. Staels FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci 28 2007 236 243 (Pubitemid 46661001)
4. R.W. Clark, T.A. Sutfin, R.B. Ruggeri, A.T. Willauer, E.D. Sugarman, and G. Magnus-Aryitey et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 24 2004 490 497 (Pubitemid 38326143)
5. T. Claudel, E. Sturm, H. Duez, I.P. Torra, A. Sirvent, and V. Kosykh et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element J Clin Invest 109 2002 961 971 (Pubitemid 34275117)
6. S.M. Clee, H. Zhang, N. Bissada, L. Miao, E. Ehrenborg, and P. Benlian et al. Relationship between lipoprotein lipase and high density lipoprotein cholesterol in mice: modulation by cholesteryl ester transfer protein and dietary status J Lipid Res 38 1997 2079 2089 (Pubitemid 27468016)
7. H.R. Davis, and E.P. Veltri Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia J Atheroscler Thromb 14 2007 99 108
8. H.R. Davis Jr., K.K. Pula, K.B. Alton, R.E. Burrier, and R.W. Watkins The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs Metabolism 50 2001 1234 1241 (Pubitemid 33034709)
9. T. Fujioka, F. Nara, Y. Tsujita, J. Fukushige, M. Fukami, and M. Kuroda The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats Biochim Biophys Acta 1254 1995 7 12
10. C. Galman, I. Arvidsson, B. Angelin, and M. Rudling Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood J Lipid Res 44 2003 859 866
11. C.A. Gonzalez, A.F. Rubio-Guerra, A. Pavia, F.J. Redding, J.L. Cervantes, and J.L. Zacarias et al. Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy Clin Drug Investig 27 2007 333 337 (Pubitemid 46789886)
12. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, and B.A. Franklin et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752 (Pubitemid 41532612)
13. A. Gupta, V. Guyomard, M.J. Zaman, H.U. Rehman, and P.K. Myint Systematic review on evidence of the effectiveness of cholesterol-lowering drugs Adv Ther 27 2010 348 364
14. H. Huang, Y. Yu, Z. Gao, Y. Zhang, C. Li, and X. Xu et al. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists J Med Chem 55 2012 7037 7053
15. W. Insull Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review South Med J 99 2006 257 273
16. R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon, and J. Cote et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914 (Pubitemid 350192656)
17. J.A. McIntyre Torcetrapib. Drugs Future 30 2005 344 349
18. T. Nishimoto, Y. Amano, R. Tozawa, E. Ishikawa, Y. Imura, and H. Yukimasa et al. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro Br J Pharmacol 139 2003 911 918 (Pubitemid 36877390)
19. S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, and W.T. Duggan et al. Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316 (Pubitemid 46513296)
20. G. Porez, J. Prawitt, B. Gross, and B. Staels Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease J Lipid Res 53 2012 1723 1737
21. M. Shiomi, S. Yamada, Y. Amano, T. Nishimoto, and T. Ito Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions Br J Pharmacol 154 2008 949 957 (Pubitemid 351915051)
22. C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, and F.J. Gonzalez Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 2000 731 744
23. N.J. Stone, S. Bilek, and S. Rosenbaum Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options Am J Cardiol 96 2005 53E 59E (Pubitemid 41140371)
24. T. Sudhop, D. Lutjohann, A. Kodal, M. Igel, D.L. Tribble, and S. Shah et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans Circulation 106 2002 1943 1948 (Pubitemid 35176299)
25. T. Teramoto, J. Sasaki, H. Ueshima, G. Egusa, M. Kinoshita, and K. Shimamoto et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 14 2007 155 158
26. A.H. Terpstra, F.J. Sanchez-Muniz, C.E. West, and C.J. Woodward The density profile and cholesterol concentration of serum lipoproteins in domestic and laboratory animals Comp Biochem Physiol B 71 1982 669 673
27. M. van Heek, D.S. Compton, and H.R. Davis The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys Eur J Pharmacol 415 2001 79 84 (Pubitemid 32197622)
28. M. van Heek, C. Farley, D.S. Compton, L. Hoos, and H.R. Davis Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function Br J Pharmacol 134 2001 409 417 (Pubitemid 32989139)